Mabwell Bioscience plans a secondary listing in Hong Kong to bolster development and global expansion. The move targets Hong ...

Verastem Oncology licenses VS-7375 rights from GenFleet Therapeutics, aiming to target KRAS-driven cancers. Early Phase I ...

Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million ...

Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...

US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS ...

Japanese drugmaker Eisai and US partner Biogen announced today that the US Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (US brand name ...

German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi ...

German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...

Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit ...

US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced ...

US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech ...

The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...